Edgewise Therapeutics: More Expensive Now, But Much More Derisked

Group 1 - The stock of Edgewise Therapeutics (NASDAQ: EWTX) nearly doubled after strong midstage data was released from an ongoing late-stage study targeting Becker's muscular dystrophy [1] - The company has a program that is currently in late-stage study, indicating potential for further growth and investment interest [1] Group 2 - The Total Pharma Tracker offers tools for DIY investors, including a software that provides extensive curated research material for any ticker [2] - In-house experts are available to assist investors by identifying the best investable stocks along with buy/sell strategies and alerts [2]